Alar Pharmaceuticals Inc.

Taipei Exchange 6785.TWO

Alar Pharmaceuticals Inc. EBIT for the year ending December 31, 2023: USD 12.74 M

Alar Pharmaceuticals Inc. EBIT is USD 12.74 M for the year ending December 31, 2023, a 1,301.27% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Alar Pharmaceuticals Inc. EBIT for the year ending December 31, 2022 was USD -1.06 M, a 54.21% change year over year.
  • Alar Pharmaceuticals Inc. EBIT for the year ending December 31, 2021 was USD -2.32 M, a 54.36% change year over year.
  • Alar Pharmaceuticals Inc. EBIT for the year ending December 31, 2020 was USD -5.08 M, a -147.32% change year over year.
  • Alar Pharmaceuticals Inc. EBIT for the year ending December 31, 2019 was USD -2.05 M.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Taipei Exchange: 6785.TWO

Alar Pharmaceuticals Inc.

CEO Dr. Yung-Shun Wen Ph.D.
IPO Date Oct. 5, 2020
Location
Headquarters No. 32, Keya Road
Employees 22
Sector Health Care
Industries
Pharmaceuticals Clinical Trials
Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email